Natus Medical Company Profile (NASDAQ:BABY)

About Natus Medical (NASDAQ:BABY)

Natus Medical logoNatus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Company's product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn's environment, and software systems for managing and tracking disorders and diseases for public health laboratories. The Company is organized into three strategic business units: Neurology, Newborn Care and Otometrics.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:BABY
  • CUSIP: 63905010
  • Web:
  • Market Cap: $1.12 billion
  • Outstanding Shares: 32,485,000
Average Prices:
  • 50 Day Moving Avg: $36.24
  • 200 Day Moving Avg: $37.54
  • 52 Week Range: $32.14 - $44.39
  • Trailing P/E Ratio: 33.08
  • Foreward P/E Ratio: 17.03
  • P/E Growth: 0.94
Sales & Book Value:
  • Annual Revenue: $419.22 million
  • Price / Sales: 2.67
  • Book Value: $12.94 per share
  • Price / Book: 2.66
  • EBIDTA: $66.04 million
  • Net Margins: 11.11%
  • Return on Equity: 13.24%
  • Return on Assets: 10.10%
  • Debt-to-Equity Ratio: 0.34%
  • Current Ratio: 5.08%
  • Quick Ratio: 4.46%
  • Average Volume: 317,950 shs.
  • Beta: 1.02
  • Short Ratio: 8.94

Frequently Asked Questions for Natus Medical (NASDAQ:BABY)

What is Natus Medical's stock symbol?

Natus Medical trades on the NASDAQ under the ticker symbol "BABY."

How were Natus Medical's earnings last quarter?

Natus Medical Inc (NASDAQ:BABY) announced its quarterly earnings data on Wednesday, April, 26th. The company reported $0.30 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by $0.03. The firm earned $124.70 million during the quarter, compared to analysts' expectations of $122.45 million. Natus Medical had a net margin of 11.11% and a return on equity of 13.24%. The company's revenue for the quarter was up 42.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.34 EPS. View Natus Medical's Earnings History.

When will Natus Medical make its next earnings announcement?

Natus Medical is scheduled to release their next quarterly earnings announcement on Tuesday, July, 18th 2017. View Earnings Estimates for Natus Medical.

What guidance has Natus Medical issued on next quarter's earnings?

Natus Medical issued an update on its FY17 earnings guidance on Wednesday, April, 26th. The company provided EPS guidance of $1.70-1.75 for the period, compared to the Thomson Reuters consensus estimate of $1.79. The company issued revenue guidance of $505-510 million, compared to the consensus revenue estimate of $504.33 million.Natus Medical also updated its Q2 guidance to $0.32-0.34 EPS.

Where is Natus Medical's stock going? Where will Natus Medical's stock price be in 2017?

3 equities research analysts have issued twelve-month price targets for Natus Medical's shares. Their forecasts range from $46.00 to $48.00. On average, they expect Natus Medical's share price to reach $47.00 in the next twelve months. View Analyst Ratings for Natus Medical.

Are investors shorting Natus Medical?

Natus Medical saw a decline in short interest during the month of April. As of April 13th, there was short interest totalling 2,210,729 shares, a decline of 7.0% from the March 31st total of 2,377,412 shares. Based on an average trading volume of 236,653 shares, the short-interest ratio is currently 9.3 days.

Who are some of Natus Medical's key competitors?

Who owns Natus Medical stock?

Natus Medical's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.00%), Vanguard Group Inc. (0.00%), Columbia Wanger Asset Management LLC (0.00%), Wellington Management Group LLP (0.00%), Dimensional Fund Advisors LP (0.00%) and Epoch Investment Partners Inc. (0.00%). Company insiders that own Natus Medical stock include Austin Francis Noll III, Dong Chune Christopher Chung, Doris Engibous, James B Hawkins, Jonathan Kennedy, Ken Ludlum, Kenneth M Traverso, Robert A Gunst and William M Moore. View Institutional Ownership Trends for Natus Medical.

Who sold Natus Medical stock? Who is selling Natus Medical stock?

Natus Medical's stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Wells Fargo & Company MN, Morgan Stanley, Motley Fool Asset Management LLC, JPMorgan Chase & Co., Ameriprise Financial Inc., Bank of America Corp DE and Goldman Sachs Group Inc.. Company insiders that have sold Natus Medical stock in the last year include Jonathan Kennedy and Robert A Gunst. View Insider Buying and Selling for Natus Medical.

Who bought Natus Medical stock? Who is buying Natus Medical stock?

Natus Medical's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Columbia Wanger Asset Management LLC, Wellington Management Group LLP, Epoch Investment Partners Inc., Lyon Street Capital LLC, Vanguard Group Inc., Renaissance Technologies LLC and United Services Automobile Association. View Insider Buying and Selling for Natus Medical.

How do I buy Natus Medical stock?

Shares of Natus Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Natus Medical stock cost?

One share of Natus Medical stock can currently be purchased for approximately $34.40.

Analyst Ratings

Consensus Ratings for Natus Medical (NASDAQ:BABY) (?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $47.00 (36.63% upside)

Analysts' Ratings History for Natus Medical (NASDAQ:BABY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/1/2017Benchmark Co.Reiterated RatingBuy -> Buy$55.00 -> $48.00MediumView Rating Details
2/2/2017Raymond James Financial, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
12/16/2016Off Wall StreetInitiated CoverageSellN/AView Rating Details
4/21/2016Roth CapitalReiterated RatingBuyN/AView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for Natus Medical (NASDAQ:BABY)
Earnings by Quarter for Natus Medical (NASDAQ:BABY)
Earnings History by Quarter for Natus Medical (NASDAQ:BABY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2017Q1 2017$0.33$0.30$122.45 million$124.70 millionViewN/AView Earnings Details
2/1/2017Q416$0.53$0.51$107.58 million$107.70 millionViewListenView Earnings Details
10/19/2016Q316$0.34$0.39$89.94 million$90.90 millionViewListenView Earnings Details
7/20/2016Q216$0.36$0.39$92.71 million$96.00 millionViewListenView Earnings Details
4/20/2016Q116$0.30$0.34$90.47 million$87.30 millionViewListenView Earnings Details
1/27/2016Q415$0.46$0.51$100.88 million$100.00 millionViewListenView Earnings Details
10/21/2015Q315$0.38$0.39$93.70 million$94.60 millionViewListenView Earnings Details
7/22/2015Q215$0.32$0.34$90.83 million$91.90 millionViewListenView Earnings Details
4/22/2015Q115$0.29$0.31$88.93 million$89.40 millionViewListenView Earnings Details
1/28/2015Q414$0.38$0.40$93.28 million$94.00 millionViewListenView Earnings Details
10/22/2014Q314$0.31$0.33$87.30 million$89.90 millionViewListenView Earnings Details
7/23/2014Q214$0.26$0.28$84.85 million$86.30 millionViewListenView Earnings Details
4/23/2014Q114$0.23$0.26$84.70 million$85.60 millionViewListenView Earnings Details
1/29/2014Q413$0.32$0.37$89.12 million$90.60 millionViewListenView Earnings Details
10/24/2013Q313$0.19$0.30$80.83 million$85.40 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.14$0.21$83.50 million$82.30 millionViewListenView Earnings Details
5/20/2013Q1 2013$0.11$0.15$84.47 million$85.80 millionViewListenView Earnings Details
2/28/2013Q4 2012$0.26$0.29$93.60 million$90.50 millionViewListenView Earnings Details
11/7/2012$0.14$0.15$81.37 million$80.70 millionViewN/AView Earnings Details
7/26/2012$0.11$0.12ViewN/AView Earnings Details
4/26/2012$0.05$0.07ViewN/AView Earnings Details
2/28/2012$0.12$0.14ViewN/AView Earnings Details
10/27/2011$0.06$0.07ViewN/AView Earnings Details
7/28/2011$0.18$0.13ViewN/AView Earnings Details
4/28/2011$0.11$0.13ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Natus Medical (NASDAQ:BABY)
2017 EPS Consensus Estimate: $1.80
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.32$0.32$0.32
Q2 20171$0.38$0.38$0.38
Q3 20171$0.42$0.42$0.42
Q4 20171$0.68$0.68$0.68
(Data provided by Zacks Investment Research)


Dividend History for Natus Medical (NASDAQ:BABY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Natus Medical (NASDAQ:BABY)
Insider Ownership Percentage: 4.80%
Institutional Ownership Percentage: 80.27%
Insider Trades by Quarter for Natus Medical (NASDAQ:BABY)
Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)
Insider Trades by Quarter for Natus Medical (NASDAQ:BABY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/9/2017Robert A GunstDirectorSell5,000$36.00$180,000.00View SEC Filing  
12/16/2016James B HawkinsInsiderBuy10,000$35.20$352,000.00View SEC Filing  
10/27/2016James B HawkinsInsiderBuy10,000$38.30$383,000.00View SEC Filing  
10/25/2016Jonathan KennedyCFOSell30,276$41.40$1,253,426.40View SEC Filing  
10/24/2016Jonathan KennedyCFOSell14,138$41.61$588,282.18View SEC Filing  
10/24/2016Robert A GunstDirectorSell3,250$41.92$136,240.00View SEC Filing  
9/28/2016James B HawkinsInsiderBuy10,000$38.48$384,800.00View SEC Filing  
4/26/2016Robert A GunstDirectorSell5,000$34.61$173,050.00View SEC Filing  
4/22/2016Doris EngibousDirectorSell5,000$32.68$163,400.00View SEC Filing  
4/22/2016Kenneth M TraversoVPSell7,459$33.56$250,324.04View SEC Filing  
2/17/2016Ken LudlumDirectorSell6,625$33.02$218,757.50View SEC Filing  
12/9/2015Dong Chune Christopher ChungVPSell14,000$48.78$682,920.00View SEC Filing  
11/27/2015James B. HawkinsCEOSell57,511$49.09$2,823,214.99View SEC Filing  
11/25/2015Austin Francis Noll IIIVPSell38,875$48.40$1,881,550.00View SEC Filing  
11/12/2015James B. HawkinsCEOSell42,489$47.62$2,023,326.18View SEC Filing  
10/30/2015James B. HawkinsCEOSell100,000$45.75$4,575,000.00View SEC Filing  
10/28/2015Dong Chune Christopher ChungVPSell26,000$45.73$1,188,980.00View SEC Filing  
10/28/2015Jonathan KennedyCFOSell28,958$45.72$1,323,959.76View SEC Filing  
9/15/2015William M MooreDirectorSell5,994$40.76$244,315.44View SEC Filing  
9/14/2015William M MooreDirectorSell4,000$40.27$161,080.00View SEC Filing  
9/8/2015William M MooreDirectorSell3,006$40.09$120,510.54View SEC Filing  
8/18/2015William M MooreDirectorSell3,000$45.62$136,860.00View SEC Filing  
8/13/2015William M MooreDirectorSell4,000$45.55$182,200.00View SEC Filing  
7/24/2015Robert A GunstDirectorSell4,000$45.30$181,200.00View SEC Filing  
6/15/2015William M MooreDirectorSell6,000$41.30$247,800.00View SEC Filing  
6/8/2015James B HawkinsCEOSell100,000$42.08$4,208,000.00View SEC Filing  
6/3/2015Dong Chune Christopher ChungVPSell26,000$41.01$1,066,260.00View SEC Filing  
4/28/2015Kenneth M TraversoVPSell57,233$40.80$2,335,106.40View SEC Filing  
4/24/2015Doris EngibousDirectorSell15,000$42.20$633,000.00View SEC Filing  
2/3/2015Dong Chune Christopher ChungVPSell40,000$36.64$1,465,600.00View SEC Filing  
12/9/2014Jonathan KennedyCFOSell45,833$35.67$1,634,863.11View SEC Filing  
12/8/2014William M MooreDirectorSell4,451$34.65$154,227.15View SEC Filing  
12/5/2014William M MooreDirectorSell561$34.65$19,438.65View SEC Filing  
12/2/2014William M MooreDirectorSell2,278$3,478.00$7,922,884.00View SEC Filing  
11/4/2014James B HawkinsCEOSell18,400$34.10$627,440.00View SEC Filing  
10/30/2014Robert A GunstDirectorSell15,000$33.92$508,800.00View SEC Filing  
10/28/2014Dong Chune Christopher ChungVPSell50,000$33.14$1,657,000.00View SEC Filing  
10/28/2014James B HawkinsCEOSell251,600$33.31$8,380,796.00View SEC Filing  
10/27/2014Dong Chune Christopher ChungVPSell39,521$33.09$1,307,749.89View SEC Filing  
10/24/2014Kenneth M TraversoVPSell30,000$33.33$999,900.00View SEC Filing  
9/10/2014William M MooreDirectorSell2,200$29.30$64,460.00View SEC Filing  
9/8/2014William M MooreDirectorSell5,000$29.17$145,850.00View SEC Filing  
7/30/2014Austin Francis Noll IIIVPSell23,500$29.42$691,370.00View SEC Filing  
5/30/2014Ken LudlumDirectorSell2,500$24.77$61,925.00View SEC Filing  
2/24/2014James HawkinsCEOSell75,000$25.88$1,941,000.00View SEC Filing  
2/13/2014James HawkinsCEOSell96,046$24.77$2,379,059.42View SEC Filing  
2/4/2014James HawkinsCEOSell16,910$25.93$438,476.30View SEC Filing  
12/4/2013James HawkinsCEOSell206,878$22.58$4,671,305.24View SEC Filing  
10/29/2013Kenneth M TraversoVPSell25,000$19.54$488,500.00View SEC Filing  
9/12/2013Doris EngibousDirectorSell33,750$13.53$456,637.50View SEC Filing  
9/12/2013Kenneth M TraversoVPSell4,225$13.89$58,685.25View SEC Filing  
8/19/2013Dong Chune Christopher ChungVPSell5,818$12.78$74,354.04View SEC Filing  
8/19/2013James HawkinsCEOSell22,190$12.78$283,588.20View SEC Filing  
6/5/2013Kenneth M TraversoVPSell22,682$14.30$324,352.60View SEC Filing  
6/3/2013Kenneth M TraversoVPSell7,318$14.50$106,111.00View SEC Filing  
5/28/2013Steven J MurphyVPSell10,000$14.42$144,200.00View SEC Filing  
3/12/2013Robert A GunstDirectorBuy5,000$13.40$67,000.00View SEC Filing  
11/27/2012Robert A GunstDirectorBuy10,000$11.66$116,600.00View SEC Filing  
11/9/2012Kenneth M TraversoVPSell49,885$11.19$558,213.15View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Natus Medical (NASDAQ:BABY)
Latest Headlines for Natus Medical (NASDAQ:BABY)
DateHeadline logoCommit To Purchase Natus Medical At $30, Earn 11.8% Annualized Using Options - Nasdaq - May 18 at 3:46 PM logoNatus Medical Inc (BABY) Receives Consensus Recommendation of "Hold" from Brokerages - May 13 at 12:46 AM logoNatus Medical to Host Analyst Day on June 22nd - May 11 at 8:11 AM logoNatus Medical Inc. Fell 11% in April. Here's Why. - May 8 at 8:42 PM logoNatus Medical Inc. Fell 11% in April. Here's Why. - May 8 at 4:34 PM logoNatus Medical Inc (BABY) Short Interest Down 7.0% in April - May 6 at 8:32 PM logoNatus Medical Inc (BABY) Expected to Post Earnings of $0.33 Per Share - May 5 at 10:21 PM logoSomewhat Favorable News Coverage Likely to Affect Natus Medical (BABY) Share Price - May 4 at 4:26 PM logoRSI Alert: Natus Medical (BABY) Now Oversold - May 2 at 10:25 AM logoNatus Medical's (BABY) "Buy" Rating Reaffirmed at Benchmark Co. - May 1 at 11:40 PM logoTheStreet Lowers Natus Medical Inc (BABY) to C+ - May 1 at 6:44 PM logoNatus Medical (BABY) Receives Daily Coverage Optimism Rating of 0.46 - May 1 at 12:16 PM logoNatus Medical Inc (BABY) Stock Rating Lowered by Zacks Investment Research - April 29 at 1:03 AM logoNatus Medical (BABY) Given Daily Media Impact Score of 0.09 - April 28 at 8:24 PM logoFY2017 EPS Estimates for Natus Medical Inc Reduced by William Blair (BABY) - April 28 at 5:22 PM logoNatus Medical, Inc. – Value Analysis (NASDAQ:BABY) : April 28, 2017 - April 28 at 4:46 PM logoNatus Medical Inc: This BABY Has Some Growing Pains - Motley Fool - April 28 at 2:16 AM logoNatus Medical Inc: This BABY Has Some Growing Pains - April 27 at 9:14 PM logoLawsuit for Investors in NASDAQ: BABY Shares Against Natus Medical Inc. Announced by Shareholders Foundation - Yahoo Finance - April 27 at 4:14 PM logoEdited Transcript of BABY earnings conference call or presentation 26-Apr-17 3:00pm GMT - April 27 at 4:14 PM logoNatus Medical, Inc. breached its 50 day moving average in a Bearish Manner : BABY-US : April 27, 2017 - April 27 at 4:14 PM logoBABY Crosses Below Key Moving Average Level - April 26 at 4:07 PM logoNatus Medical Inc (BABY) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPS - April 26 at 3:48 PM logoWhy Natus Medical Inc. Sank Today - April 26 at 1:01 PM logoNatus Medical Announces First Quarter 2017 Financial Results - April 26 at 10:59 AM logoNatus Medical misses 1Q profit forecasts - April 26 at 8:16 AM logoSomewhat Favorable Press Coverage Somewhat Likely to Impact Natus Medical (BABY) Stock Price - April 25 at 2:58 PM logoLawsuit for Investors in NASDAQ: BABY Shares Against Natus Medical Inc. Announced by Shareholders Foundation - April 25 at 12:43 PM logoNatus Medical (BABY) Given Daily News Impact Score of -0.12 - April 18 at 12:22 PM logoNatus Medical Inc (BABY) Given Average Rating of "Hold" by Brokerages - April 18 at 12:52 AM logoNatus Medical Inc (BABY) Expected to Post Quarterly Sales of $122.48 Million - April 16 at 7:44 AM logoNatus Medical (BABY) Receiving Somewhat Critical Media Coverage, Report Finds - April 15 at 10:55 AM logo$0.33 Earnings Per Share Expected for Natus Medical Inc (BABY) This Quarter - April 14 at 10:18 PM logoNatus Medical to Hold 2017 First Quarter Financial Results Conference Call on April 26th - April 12 at 7:28 AM logoNatus Medical Inc (BABY) Rating Increased to Hold at Zacks Investment Research - April 4 at 11:10 PM logoDEADLINE TOMORROW: Lundin Law PC Announces Securities Class Action Lawsuit against Natus Medical Incorporated and Reminds Investors with Losses to Contact the Firm - March 30 at 9:14 PM logoNatus Medical Inc (BABY) Upgraded by Zacks Investment Research to "Hold" - March 30 at 9:09 AM logoSHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Natus Medical ... - Business Wire (press release) - March 30 at 2:06 AM logoNATUS 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against Natus Medical Incorporated - (BABY) - March 29 at 12:44 PM logoMARCH 31 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Natus Medical Incorporated and Encourages Investors with Losses to Contact the Firm - March 29 at 12:44 PM logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Natus ... - Business Wire (press release) - March 28 at 12:31 PM logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Natus Medical Incorporated and Encourages Investors with Losses to Contact the Firm - March 28 at 12:30 PM logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Natus Medical Incorporated of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 31, 2017 - BABY - March 28 at 12:30 PM logoSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Investors in Natus Medical Incorporated of Upcoming Lead Plaintiff Deadline - March 25 at 3:46 PM logoEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Natus Medical Incorporated - BABY - March 24 at 9:12 PM logoSHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Natus Medical Incorporated and Encourages Investors with Losses to Contact the Firm - March 24 at 4:12 PM logoZacks Investment Research Upgrades Natus Medical Inc (BABY) to "Hold" - March 24 at 9:44 AM logoSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Investors in Natus Medical Incorporated of Imminent Lead Plaintiff Deadline - March 23 at 9:14 PM logoDEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Natus Medical Incorporated (BABY) & Lead Plaintiff Deadline: March 31, 2017 - March 23 at 4:13 PM logoSHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Natus Medical Incorporated and Encourages Investors with Losses to Contact the Firm - March 23 at 4:13 PM



Natus Medical (BABY) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff